Oxehealth

Highlights ⭐

• World's first accreditation: In 2018, the British Standards Institute (BSI) has accredited Oxehealth's vital signs measurement software as a Class IIa medical device in Europe. This was the first time that software enabling a digital video camera sensor to remotely measure vital signs has been approved as a medical device. 🔗
• Cleared by the FDA: In March 2021, the U.S. FDA granted a De Novo clearance for the Oxehealth Vital Signs product, which is incorporated into Oxevision - the vision-based patient monitoring and management platform delivered as software as a service. 🔗
• Helping reduce falls: Oxehealth have been working with Coventry and Warwickshire Partnership NHS Trust (CWPT) to reduce falls and associated injuries in their 24-bed inpatient dementia facility, Manor Hospital. The clinical study, run for almost two years, has found that a 48% reduction in falls at night has been achieved, which is the equivalent to a reduction of 94 falls during the period. 🔗
• Helped fight COVID-19: During the COVID-19 pandemic, the company has delivered a series of system-wide updates during, enabling clinicians to quickly and clearly decide if a patient's breathing rate and pulse rate has been on a trajectory which may require more detailed observations or other care intervention.
• Beyond healthcare: In addition to the healthcare setting, Oxehealth has also been growing in care homes, prisons and police facilities. 🔗
• Expansion ready: As of June 2022, Oxehealth is present in the markets of the UK, Sweden and the U.S. with the idea to expand to rest of the Europe and score new clients in existing markets.